<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39417469</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-4464</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>9</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Cadernos de saude publica</Title><ISOAbbreviation>Cad Saude Publica</ISOAbbreviation></Journal><ArticleTitle>[Effect of previous exposure to COVID-19, occurrence of spikes, and type of vaccine on the humoral immune response of institutionalized older adults].</ArticleTitle><Pagination><StartPage>e00155023</StartPage><MedlinePgn>e00155023</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00155023</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/0102-311XES155023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0102-311X2024000901414</ELocationID><Abstract><AbstractText>This study evaluated the explanatory factors of humoral immune response in older adults admitted to long-term care institutions in Buenos Aires, Argentina, up to 180 days after vaccination. An open-label, prospective, multicenter cohort study was conducted with volunteers who received two doses of the Sputnik V, Sinopharm, or AZD1222 vaccines. Plasma samples were analyzed at 0 and 21 days after the first dose, 21 days after the second dose, and 120 and 180 days after the first dose. Marginal linear models and generalized additives mixed models were adjusted to determine the behavior of anti-spike IgG antibody concentration over time according to exposure group (naïve/no-naïve) and vaccine. Occurrence of an outbreak of COVID-19 in long-term care institutions and comorbidities were the covariates analyzed. A total of 773 participants were included, with a mean age of 83 years (IQR: 76-89). Results showed that antibody levels in the naïve: Sinopharm group were significantly lower to the other groups (p &lt; 0.05). Antibody levels in the no-naïve: Sinopharm group were similar to those in the naïve group who received AZD1222 (p = 0.945) or Sputnik V (p = 1). Participants exposed to outbreaks in long-term care institutions had significantly higher antibody levels, regardless of exposure group and vaccine (p &lt; 0.001). In conclusion, previous exposure to COVID-19, type of vaccine, and admittance into a long-term care institution with a history of outbreaks are factors to be considered in future epidemic events with transmission dynamics and immunological mechanisms similar to COVID-19, in populations similar to the one analyzed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aguirre</LastName><ForeName>Fernanda</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-3979-865X</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marro</LastName><ForeName>María Jimena</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-9483-2304</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Pamela E</ForeName><Initials>PE</Initials><Identifier Source="ORCID">0000-0003-3827-3760</Identifier><AffiliationInfo><Affiliation>Fundación Instituto Leloir, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rall</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0004-7486-7392</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Servicios Sociales para Jubilados y Pensionados, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miglietta</LastName><ForeName>Esteban A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-4898-7794</Identifier><AffiliationInfo><Affiliation>Fundación Instituto Leloir, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Lucía A López</ForeName><Initials>LAL</Initials><Identifier Source="ORCID">0000-0003-4394-1604</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poncet</LastName><ForeName>Verónica</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-8155-5478</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascuale</LastName><ForeName>Carla A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-7243-6327</Identifier><AffiliationInfo><Affiliation>Fundación Instituto Leloir, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballejo</LastName><ForeName>Christian A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-7346-5701</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricardo</LastName><ForeName>Tamara</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0921-2611</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miragaya</LastName><ForeName>Yanina</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0005-2754-5857</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Servicios Sociales para Jubilados y Pensionados, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamarnik</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9789-4105</Identifier><AffiliationInfo><Affiliation>Fundación Instituto Leloir, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Andrés H</ForeName><Initials>AH</Initials><Identifier Source="ORCID">0000-0002-5844-6609</Identifier><AffiliationInfo><Affiliation>Fundación Instituto Leloir, Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Andrea P</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-4791-9706</Identifier><AffiliationInfo><Affiliation>Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán", Mar del Plata, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList><VernacularTitle>Efecto de la exposición previa a COVID-19, ocurrencia de brotes y tipo de vacuna en la respuesta inmune humoral de adultos mayores institucionalizados.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Cad Saude Publica</MedlineTA><NlmUniqueID>8901573</NlmUniqueID><ISSNLinking>0102-311X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001118" MajorTopicYN="N" Type="Geographic">Argentina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>El objetivo de este trabajo fue evaluar los factores explicativos de la respuesta inmune humoral en adultos mayores de establecimientos de estancia prolongada de Buenos Aires, Argentina, hasta 180 días post vacunación. Se utilizó un diseño de cohorte abierta, prospectiva, multicéntrica, con voluntarios que recibieron dos dosis de vacunas Sputnik V, Sinopharm o AZD1222. Se analizaron muestras de plasma en los tiempos 0, 21 días post primera dosis, 21 días post segunda dosis, 120 y 180 días post primera dosis. Se ajustaron modelos lineales marginales y aditivos generalizados mixtos para evaluar el comportamiento de la concentración de anticuerpos IgG anti-Spike en el tiempo según grupo de exposición (naïve/no-naïve) y vacuna. Las covariables analizadas fueron: ocurrencia de brote de COVID-19 en establecimientos de estancia prolongada y comorbilidades. Se incluyeron en el análisis 773 participantes con una mediana de edad de 83 años (RIQ: 76-89). Al final del estudio, los niveles de anticuerpos del grupo naïve: Sinopharm fueron significativamente menores que el resto de los grupos (p &lt; 0,05); los del no-naïve: Sinopharm resultaron similares a los naïve que recibieron AZD1222 (p = 0,945) o Sputnik V (p = 1). Los participantes expuestos a brotes en establecimientos de estancia prolongada presentaron niveles de anticuerpos significativamente mayores, independientemente del grupo de exposición y la vacuna (p &lt; 0,001). Concluimos que la exposición previa a COVID-19, el tipo de vacuna y la pertenencia a un establecimiento de estancia prolongada con antecedente de brote son factores a considerar frente a futuros eventos epidémicos con dinámicas de transmisión y mecanismos inmunológicos similares al COVID-19, en poblaciones similares a la analizada en este trabajo.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="por"><AbstractText>Este estudo teve como objetivo avaliar os fatores explicativos da resposta imune humoral em idosos em instituições de longa permanência em Buenos Aires, Argentina, até 180 dias após a vacinação. Foi realizado um estudo de coorte aberto, prospectivo e multicêntrico, com voluntários que receberam duas doses das vacinas Sputnik V, Sinopharm ou AZD1222. As amostras de plasma foram analisadas nos tempos 0, 21 dias após a primeira dose, 21 dias após a segunda dose, 120 e 180 dias após a primeira dose. Os modelos lineares marginais e os aditivos generalizados mistos foram ajustados para determinar o comportamento da concentração de anticorpos IgG anti-Spike ao longo do tempo de acordo com o grupo de exposição (naïve/no-naïve) e vacina. As covariáveis analisadas foram ocorrência de pico de COVID-19 nas instituições de longa permanência e comorbidades. Foram incluídos 773 participantes, com média de idade de 83 anos (IIQ: 76-89). Os resultados apontaram níveis de anticorpos do grupo naïve: Sinopharm significativamente mais baixos do que os outros grupos (p &lt; 0,05); e as variáveis do grupo no-naïve: Sinopharm foram semelhantes à do grupo naïve que recebeu AZD1222 (p = 0,945) ou Sputnik V (p = 1). Os participantes expostos a picos nas instituições de longa permanência apresentaram níveis de anticorpos significativamente maiores, independentemente do grupo de exposição e da vacina (p &lt; 0,001). Conclui-se que a exposição prévia à COVID-19, tipo de vacina e adesão a uma instituição de longa permanência com histórico de pico são fatores a serem considerados em futuros eventos epidêmicos com dinâmica de transmissão e mecanismos imunológicos semelhantes à COVID-19, em populações semelhantes à analisada neste trabalho.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>16</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>7</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39417469</ArticleId><ArticleId IdType="pmc">PMC11469675</ArticleId><ArticleId IdType="doi">10.1590/0102-311XES155023</ArticleId><ArticleId IdType="pii">S0102-311X2024000901414</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC COVID-19 Response Team Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343–346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7725513</ArticleId><ArticleId IdType="pubmed">32214079</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China a retrospective cohort study. Lancet. 2020;395:1054–1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedreáñez-Santana AB, Mosquera-Sulbarán JA, Muñoz-Castelo NE. Envejecimiento inflamatorio e inmunosenescencia, la posible respuesta a la severidad de la COVID-19 en los adultos mayores. Kasmera. 2020;48:e48233906</Citation></Reference><Reference><Citation>Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM. Aging in COVID-19 vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205–101205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemenesi G, Kornya L, Tóth GE, Kurucz K, Zeghbib S, Somogyi BA. Nursing homes and the elderly regarding the COVID-19 pandemic situation report from Hungary. GeroScience. 2020;42:1093–1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232926</ArticleId><ArticleId IdType="pubmed">32426693</ArticleId></ArticleIdList></Reference><Reference><Citation>Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775–1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">32203977</ArticleId></ArticleIdList></Reference><Reference><Citation>Logar S. Care home facilities as new COVID-19 hotspots lombardy Region (Italy) case study. Arch Gerontol Geriatr. 2020;89:104087–104087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189837</ArticleId><ArticleId IdType="pubmed">32388072</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussien H, Nastasa A, Apetrii M, Nistor I, Petrovic M, Covic A. Different aspects of frailty and COVID-19 points to consider in the current pandemic and future ones. BMC Geriatr. 2021;21:389–389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8236311</ArticleId><ArticleId IdType="pubmed">34176479</ArticleId></ArticleIdList></Reference><Reference><Citation>Presidencia de la Nación  Aislamiento social, preventivo y obligatorio. Decreto
297/2020. Boletín Oficial de la República Argentina. 2020 Mar 19; https://www.boletinoficial.gob.ar/detalleAviso/primera/227042/20200320</Citation></Reference><Reference><Citation>Instituto Nacional de Epidemiología Dr. Juan H. Jara . Estudios de brotes de enfermedad por coronavirus en establecimientos de estancia prolongada de Mar del Plata - Batán (agosto a noviembre de 2020). Mar del Plata: Administración Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbrán; 2020.</Citation></Reference><Reference><Citation>Ministerio de Salud de Argentina  Plan estratégico para la vacunación contra la COVID-19 en la República
Argentina.  [15/Ago/2023].  
 https://www.argentina.gob.ar/sites/default/files/coronavirus-vacuna-plan-estrategico-vacunacion-covid-19-diciembre-2020.pdf
.</Citation></Reference><Reference><Citation>Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics. 2020;10:7448–7464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7330865</ArticleId><ArticleId IdType="pubmed">32642005</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671–681.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto Nacional de Estadísticas y Censos  Proyecciones por departamento. Población estimada al 1 de julio de cada
año calendario por sexo, según departamento. Provincia de Buenos Aires. Años
2010-2025.  [18/Jul/2023].  
 https://www.indec.gob.ar/indec/web/Nivel4-Tema-2-24-119
.</Citation></Reference><Reference><Citation>Ministerio de Salud de Argentina  Estado de situación de salud de las personas mayores, año 2020.  [14/Ago/2023].  
 https://bancos.salud.gob.ar/sites/default/files/2022-11/situacion_personas_mayores_23-11-2022.pdf
.</Citation></Reference><Reference><Citation>Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, Costa Navarro GS, Sanchez L, Perazzi B, et al. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog. 2021;17:e1009161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808630</ArticleId><ArticleId IdType="pubmed">33444413</ArticleId></ArticleIdList></Reference><Reference><Citation>Marttila M. censlm: censored linear models.  [09/Sep/2024].  
 https://github.com/mikmart/censlm
.</Citation></Reference><Reference><Citation>Pekár S, Brabec M. Marginal models via GLS a convenient yet neglected tool for the analysis of correlated data in the behavioural sciences. Ethology. 2016;122:621–631.</Citation></Reference><Reference><Citation>Pinheiro JC, Bates DM. Mixed-effects models in S and S-PLUS. Nueva York: Springer; 2020.</Citation></Reference><Reference><Citation>Wood SN. Generalized additive models: an introduction with R. 2ª Ed. Londres: Chapman and Hall/CRC; 2017.</Citation></Reference><Reference><Citation>Rodriguez PE, Silva AP, Miglietta EA, Rall P, Pascuale CA, Ballejo C. Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina. Front Immunol. 2022;13:992370–992370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9549602</ArticleId><ArticleId IdType="pubmed">36225925</ArticleId></ArticleIdList></Reference><Reference><Citation>Rearte A, Castelli JM, Rearte R, Fuentes N, Pennini V, Pesce M. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina a test-negative, case-control, and retrospective longitudinal study. Lancet. 2022;399:1254–1264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8923678</ArticleId><ArticleId IdType="pubmed">35303473</ArticleId></ArticleIdList></Reference><Reference><Citation>González S, Olszevicki S, Salazar M, Calabria A, Regairaz L, Marín L. Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79 a retrospective cohort study in Argentina. EClinicalMedicine. 2021;40:101126–101126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8435263</ArticleId><ArticleId IdType="pubmed">34541480</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchia A, Ferrante D, Angeleri P, Biscayart C, Mariani J, Esteban S. Evaluation of a COVID-19 vaccine vampaign and SARS-CoV-2 infection and mortality among adults aged 60 years and older in a middle-income country. JAMA Netw Open. 2021;4:e2130800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8556631</ArticleId><ArticleId IdType="pubmed">34714342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminska D, Deborska-Materkowska D, Koscielska-Kasprzak K, Mazanowska O, Remiorz A, Poznanski P. Immunity after COVID-19 recovery and vaccination similarities and differences. Vaccines (Basel) 2022;10:1068–1068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9322013</ArticleId><ArticleId IdType="pubmed">35891232</ArticleId></ArticleIdList></Reference><Reference><Citation>Upreti S, Samant M. A review on immunological responses to SARS-CoV-2 and various COVID-19 vaccine regimens. Pharm Res. 2022;39:2119–2134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9247891</ArticleId><ArticleId IdType="pubmed">35773445</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Evidence assessment: Sinopharm/BBIBP COVID-19 vaccine.  [25/Mar/2024].  
 https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf
.</Citation></Reference><Reference><Citation>Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung PK. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J Infect Dis. 2022;225:1129–1140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689804</ArticleId><ArticleId IdType="pubmed">34888688</ArticleId></ArticleIdList></Reference><Reference><Citation>Adjobimey T, Meyer J, Sollberg L, Bawolt M, Berens C, Kovacevic P. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 vaccines. Front Immunol. 2022;13:917905–917905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254618</ArticleId><ArticleId IdType="pubmed">35799790</ArticleId></ArticleIdList></Reference><Reference><Citation>Eberhardt AT, Simoncini M, Piña C, Galoppo G, Parachú-Marco V, Racca A. Preceding anti-spike IgG levels predicted risk and severity of COVID-19 during the Omicron-dominant wave in Santa Fe city, Argentina. Epidemiol Infect. 2022;150:e187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9947048</ArticleId><ArticleId IdType="pubmed">36325837</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Jiang L, Tian T, Li W, Pan Y, Wang Y. Efficacy and safety of COVID-19 vaccination in older adults a systematic review and meta-analysis. Vaccines (Basel) 2022;11:33–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9862835</ArticleId><ArticleId IdType="pubmed">36679878</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgilio E, Trevisan C, Abbatecola A, Malara A, Palmieri A, Fedele G. Diabetes affects antibody response to SARS-CoV-2 vaccination in older residents of long-term care facilities data from the GeroCovid Vax study. Diabetes Care. 2022;45:2935–2942.</Citation><ArticleIdList><ArticleId IdType="pubmed">36201657</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinh DC, Gouin JP, Cruz-Santiago D, Canac-Marquis M, Bernier S, Bobeuf F. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER) an interim report from a prospective observational cohort study. Lancet Healthy Longev. 2022;3:e166–e175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863504</ArticleId><ArticleId IdType="pubmed">35224524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G. Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine but strong initial responses to a third dose. J Infect Dis. 2022;226:983–994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129202</ArticleId><ArticleId IdType="pubmed">35543278</ArticleId></ArticleIdList></Reference><Reference><Citation>Seiffert P, Konka A, Kasperczyk J, Kawa J, Lejawa M, Maslanka-Seiffert B. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility relation with age, frailty and prior infection status. Biogerontology. 2022;23:53–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8684786</ArticleId><ArticleId IdType="pubmed">34923608</ArticleId></ArticleIdList></Reference><Reference><Citation>Glück V, Tydykov L, Mader AL, Warda AS, Bertok M, Weidlich T. Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects. Infection. 2022;50:1475–1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995884</ArticleId><ArticleId IdType="pubmed">35403960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease a systematic review and meta-regression. Lancet Infect Dis. 2023;23:556–567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N, Barouch DH. SARS-CoV-2 hybrid immunity the best of both worlds. J Infect Dis. 2023;228:1311–1313.</Citation><ArticleIdList><ArticleId IdType="pubmed">37592872</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon MML, Rybkina K, Kato Y, Kubota M, Matsumoto R, Bloom NI. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci Immunol. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626868</ArticleId><ArticleId IdType="pubmed">34618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodda LB, Morawski PA, Pruner KB, Fahning ML, Howard CA, Franko N. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185:1588–1601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926873</ArticleId><ArticleId IdType="pubmed">35413241</ArticleId></ArticleIdList></Reference><Reference><Citation>Major M, Majowicz SE, Oremus M, Jimenez LJ, Angulo FJ, Horton S. Systematic literature review of SARS-CoV-2 seroprevalence surveys in Canada through April 2021. IJID Reg. 2022;4:157–164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9335354</ArticleId><ArticleId IdType="pubmed">35919829</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijh R, Ghafari C, Hayden A, Schwandt M, Sekirov I, Morshed M. Serological survey following SARS-COV-2 outbreaks at long-term care facilities in metro Vancouver, British Columbia implications for outbreak management and infection control policies. Am J Infect Control. 2021;49:649–652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568771</ArticleId><ArticleId IdType="pubmed">33086096</ArticleId></ArticleIdList></Reference><Reference><Citation>Crèvecoeur J, Hens N, Neyens T, Larivière Y, Verhasselt B, Masson H. Change in COVID19 outbreak pattern following vaccination in long-term care facilities in Flanders, Belgium. Vaccine. 2022;40:6218–6224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9472804</ArticleId><ArticleId IdType="pubmed">36127210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson WW, Keaton AA, Ochoa LG, Hatfield KM, Gable P, Walblay KA. Outbreaks of SARS-CoV-2 infections in nursing homes during periods of Delta and Omicron predominance, United States, July 2021-March 2022. Emerg Infect Dis. 2023;29:761–770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10045674</ArticleId><ArticleId IdType="pubmed">36918377</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrotri M, Krutikov M, Nacer-Laidi H, Azmi B, Palmer T, Giddings R. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI) a prospective cohort study. Lancet Healthy Longev. 2022;3:e470–e480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9252508</ArticleId><ArticleId IdType="pubmed">35813279</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguirre MF, Silva AP, Marro MJ, López Miranda LA, Amezqueta GA, Poncet VE, et al. Abordaje epidemiológico en establecimiento de estancia prolongada de adultos mayores con antecedente de brote de COVID-19. Rev Argent Salud Pública. 2021;13(Suppl COVID-19):e21</Citation></Reference><Reference><Citation>Ashktorab H, Pizuomo A, González NAF, Villagrana EDC, Herrera-Solís ME, Cardenas G, et al.  A comprehensive analysis of COVID-19 impact in Latin
America. Res Sq. 2021 Jan 08; https://www.researchsquare.com/article/rs-141245/v1</Citation></Reference><Reference><Citation>Hashan MR, Smoll N, King C, Ockenden-Muldoon H, Walker J, Wattiaux A. Epidemiology and clinical features of COVID-19 outbreaks in aged care facilities a systematic review and meta-analysis. EClinicalMedicine. 2021;33:100771–100771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7917447</ArticleId><ArticleId IdType="pubmed">33681730</ArticleId></ArticleIdList></Reference><Reference><Citation>Oviedo Rouco S, Rodriguez PE, Miglietta EA, Rall P, Ledesma MMGL, Varese A. Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people. Lancet Infect Dis. 2022;22:1118–1119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9239573</ArticleId><ArticleId IdType="pubmed">35777383</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>